Synageva BioPharma™ to Present at the Cowen and Company 33rd Annual Health Care Conference

  Synageva BioPharma™ to Present at the Cowen and Company 33rd Annual Health
  Care Conference

Cowen Group Healthcare Conference 2013

Business Wire

LEXINGTON, Mass. -- February 26, 2013

Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare disorders,
today announced its presentation at the upcoming Cowen and Company 33^rd
Annual Health Care Conference.

Sanj K. Patel, President and Chief Executive Officer of Synageva, is scheduled
to present on Tuesday, March 5, 2013, at 10:40 a.m. EST. The presentation will
be webcast live and may be accessed from the “Webcasts & Presentations”
section of the Investor Relations tab on the home page of Synageva’s website

About Synageva’s Lead Program

Sebelipase alfa (SBC-102) is a recombinant form of the human LAL enzyme under
development by Synageva as an enzyme replacement therapy for LAL Deficiency, a
lysosomal storage disorder (LSD). Synageva is currently evaluating sebelipase
alfa in global clinical trials for both early and late onset LAL Deficiency.
Sebelipase alfa has been granted orphan designations by the U.S. Food and Drug
Administration (FDA), the European Medicines Agency, and the Japanese Ministry
of Health, Labour and Welfare. Additionally, sebelipase alfa received “fast
track” designation by the FDA.

About LAL Deficiency

LAL Deficiency is a rare autosomal recessive LSD caused by a marked decrease
in LAL enzyme activity. Late onset LAL Deficiency, sometimes called
Cholesteryl Ester Storage Disease (CESD), affects both children and adults. In
these patients, the buildup of fatty material in the liver and blood vessel
walls may lead to liver cirrhosis, liver failure and accelerated
atherosclerotic events. Early onset LAL Deficiency, sometimes called Wolman
disease, affects infants and is characterized by severe malabsorption, growth
failure and liver failure, and is usually fatal within the first six months of
life. There are no approved pharmacological therapies for LAL Deficiency.
Success with stem cell and liver transplant appears to be limited by
procedure-related morbidity and mortality.

About Synageva BioPharma Corp.

Synageva is a clinical stage biopharmaceutical company focused on the
discovery, development, and commercialization of therapeutic products for
patients with life-threatening rare diseases and unmet medical need. Synageva
has several protein therapeutics in its drug development pipeline. The company
has a team with a proven record of bringing therapies to patients with rare

Further information regarding Synageva BioPharma Corp. is available at

Forward-Looking Statements

This news release and oral statements made from time to time by Synageva
representatives in respect of the same subject matter may contain
“forward-looking statements” under the provisions of the Private Securities
Litigation Reform Act of 1995. Such statements can be identified by
introductory words such as “expects,” “plans,” “intends,” “believes,” “will,”
“estimates,” “forecasts,” “projects,” or words of similar meaning and by the
fact that they do not relate strictly to historical or current facts. Many
factors may cause actual results to differ materially from forward-looking
statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known, including those identified under the
heading “Risk Factors” in the Company’s prospectus supplement filed with the
Securities and Exchange Commission (the “SEC”) on January3, 2013, and other
filings Synageva periodically makes with the SEC and others of which are not.

“Dedicated to Rare Diseases®” is a registered trademark and “Synageva
BioPharma™” is a trademark of Synageva BioPharma Corp.


Synageva BioPharma Corp.
Matthew Osborne, 781-357-9947
Press spacebar to pause and continue. Press esc to stop.